drug
LEUCOVORIN CALCIUM
Marketedupdated 3mo agoby Avyxa Pharma LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 5all catalysts(6)
approval · 6
Jul 8, 1983
approval
WELLCOVORIN (LEUCOVORIN CALCIUM) — FDA approval
LEUCOVORIN CALCIUM
→
Apr 14, 1993
approval
WELLCOVORIN (LEUCOVORIN CALCIUM) — FDA approval
LEUCOVORIN CALCIUM
→
Jun 6, 1996
approval
WELLCOVORIN (LEUCOVORIN CALCIUM) — FDA approval
LEUCOVORIN CALCIUM
→
Nov 12, 2025
approval
LEUCOVORIN CALCIUM — FDA approval
LEUCOVORIN CALCIUM
→
Feb 3, 2026
approval
VYKOURA (LEUCOVORIN CALCIUM) — FDA approval
LEUCOVORIN CALCIUM
→
Mar 9, 2026
approval
WELLCOVORIN (LEUCOVORIN CALCIUM) — FDA approval
LEUCOVORIN CALCIUM
→
Trials studying LEUCOVORIN CALCIUM
- phase2A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer
- phase1A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
- phase3A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- phase3A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
- phase2A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
- phase3Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
- phase2Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
- phase2A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 23, 2044
~18.4 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (3)
- Dec 23, 2044formulationUS 12564592
- Dec 23, 2044formulationUS 12564592
- Dec 23, 2044formulationUS 12564592
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 17m ago
Found something off?
comments(0)
5-min edit window · permanent after that